Here is some other vaccine news of note for the week.
China has withheld shipments of the H7N9 strain to the U.S. for research, according to The New York Times.
CDC officials have been pushing HPV vaccination, and in 2017—just as in the previous four years—those efforts yielded only a slight increase.
CSL's flu vaccine unit Seqirus posted $1.09 billion in sales during its 2018 fiscal year and turned in its first-ever profit.
Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.
Profectus’ Lassa candidate is based on its VesiculoVax vaccine delivery platform, which uses vesicular stomatitis virus as vector.
Sanofi might need to work out some extraordinary measures to ensure flu vaccine supplies to the U.K. in case of a no-deal Brexit.
Bi Jingquan, who headed CFDA for three years, was asked to resign from his current position at the all-powerful State Administration for Market Regulation.